A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients with Bullous Pemphigoid
The main purpose of this study is to investigate whether the study drug, dupilumab, is effective and safe for treatment of bullous pemphigoid.
bullous pemphigoid, BP
Below are a list of criteria that would exclude from participating:
1. Forms of pemphigoid other than classic BP
2. Receiving treatments known to cause or exacerbate BP
3. Previous use of the study drug
4. Current diagnosis of hepatitis B or C
Other exclusion criteria will be discussed with the study team later
Healthy Volunteers Needed
Duration of Participation
approximately 64 weeks.
email@example.com or call 503-418-9386
Regeneron Pharmaceuticals, Inc. and Sanofi-Aventis US
$75 for each completed visit.